Kaczanowska S, Murty T, Alimadadi A, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell. 2024;42(1):35-51.e8. doi:10.1016/j.ccell.2023.11.011
Iorgulescu B, Ruthen N, Ahn R, et al. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. Frontiers in immunology. 2023;14:1297932. doi:10.3389/fimmu.2023.1297932
Ausejo-Mauleon I, Labiano S, de la Nava D, et al. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer cell. 2023. doi:10.1016/j.ccell.2023.09.001
Parry EM, Lemvigh CK, Deng S, et al. ZNF683 marks a CD8 TÂ cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer cell. 2023. doi:10.1016/j.ccell.2023.08.013
Nyman J, Denize T, Bakouny Z, et al. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell reports. Medicine. 2023;4(9):101189. doi:10.1016/j.xcrm.2023.101189
Chen D, Varanasi SK, Hara T, et al. CTLA-4 blockade induces CD4 T cell IFNγ-driven microglial phagocytosis and anti-tumor function in glioblastoma. Immunity. 2023. doi:10.1016/j.immuni.2023.07.015
Kalaany N. How nearby nutrients shape tumor growth. eLife. 2023;12. doi:10.7554/eLife.89825
Ma L, Hostetler A, Morgan DM, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023. doi:10.1016/j.cell.2023.06.002
Iorgulescu B, Braun D, Oliveira G, Keskin DB, Wu CJ. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018;10(1):87. doi:10.1186/s13073-018-0598-2
Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10(1):93. doi:10.1186/s13073-018-0605-7